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Summary
Background: Primary urethral carcinoma is a very rare
condition, and no large-scale experience with such cases
has been published. Treatment will therefore have to
follow rules established for the treatment of similar con-
ditions. Patients: Six cases of primary urethral carcinoma
(5 male, 1 female) who had been treated at our institution
between 1995 and 1999 were retrospectively analyzed. In
3 male cases, a primary urothelial carcinoma of the distal
urethra was treated by distal urethrectomy only. In 3 other
cases with locally advanced tumors and/or lymph node
metastases surgical treatment was followed by adjuvant
cisplatinum-containing chemotherapy. Results: In the 3
cases with distal urethral carcinoma, partial urethrectomy
with preservation of the penis resulted in cure, with a
follow-up of 12–71 months. In the cases with advanced
disease, adjuvant chemotherapy after surgery has re-
sulted in complete remissions in all 3 cases, with a follow-
up of 4–47 months at present. Conclusions: In localized,
noninvasive carcinoma of the distal male urethra, partial
urethrectomy seems adequate and the avoidance of
penile amputation justified. In advanced cases, after local
excision and lymphadenectomy adjuvant chemotherapy
which by necessity must follow the guidelines estab-
lished for the treatment of other urothelial or squamous
cell malignancies seems to be beneficial.
Schlüsselwörter
Urethra · Urethrakarzinom · Operative Therapie · 
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Zusammenfassung
Hintergrund: Das primäre Harnröhrenkarzinom ist eine
sehr seltene Erkrankung, und in der Literatur gibt es keine
prospektiven Serien mit größeren Fallzahlen. Die Behand-
lung wird sich daher an Erfahrungen orientieren müssen,
die bei der Behandlung ähnlicher Krankheitsbilder ge-
wonnen wurden. Patienten: Sechs Fälle von primärem
Urethralkarzinom (5 Männer, 1 Frau), die zwischen 1995
und 1999 in unserer Klinik behandelt wurden, wurden
retrospektiv analysiert. Bei 3 der männlichen Patienten
lag ein primäres Urothelkarzinom der distalen Harnröhre
vor, und es wurde eine Urethrateilresektion ohne adju-
vante Therapie durchgeführt. In den 3 anderen Fällen mit
lokal fortgeschrittenen Tumoren und/oder Lymphknoten-
befall wurde nach operativer Behandlung eine adjuvante
Cisplatin-haltige Chemotherapie durchgeführt. Ergebnisse:
In allen 3 Fällen nach Urethrateilresektion wurde eine kom-
plette Heilung bei einer Nachbeobachtung von 12–71 Mo-
naten erzielt. Bei den fortgeschrittenen Fällen mit lympho-
gener Metastasierung wurde nach adjuvanter Chemo-
therapie in allen 3 Fällen eine komplette Remission bei
einer Nachbeobachtung von bislang 4–47 Monaten er-
zielt. Schlußfolgerungen: Beim lokalisierten, nichtinvasiven
distalen Urethralkarzinom des Mannes ist eine organ-
erhaltende Strategie gerechtfertigt. In lokal fortgeschritte-
nen und/oder lymphogen metastasierten Fällen ist nach
lokaler Exzision und Lymphadenektomie eine adjuvante
Chemotherapie, die sich an den Erfahrungen der Behand-
lung von anderen Plattenepithel- und Urothelkarzinomen
orientieren muß, sinnvoll und erfolgversprechend.
Onkologie 2001;24:48–52ONKOLOGIE
The Treatment of Primary Urethral Carcinoma – the
Dilemmas of a Rare Condition: Experience with Partial
Urethrectomy and Adjuvant Chemotherapy
O.W. Hakenberg H.-J. Franke M. Froehner M.P. Wirth
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav Carus, Dresden
© 2001 S. Karger GmbH, Freiburg
Fax +49 761 4 52 0714 Accessible online at:
E-mail Information@Karger.de www.karger.com/journals/onk
www.karger.com
Dr. Oliver Hakenberg
Klinik und Poliklinik für Urologie
Universitätsklinikum Carl-Gustav Carus
Fetscherstraße 74, D-01307 Dresden (Germany)
Tel. +49 351 458-24 47, Fax -43 33
E-mail hakenberg@debitel.net
Introduction
Primary carcinoma of the urethra is a rare condition. Only
approximately 600 cases have been reported in males [1] and
about 1,200 cases in females [2]. However, although the true
incidence of urethral cancer is unknown, it is probably higher
than the number of cases reported in the literature suggests.
Urethral carcinoma represents the only  exception to the rule
that shared genitourinary malignancies are more common in
men than in women. Classification of urethral carcinoma is
done according to the location and histology of the epithelium
lining the urethra [3].The majority of cases represent squamous
cell carcinoma, and patients are generally above 50 years of
age on presentation.
In males, primary carcinomas of the urethra occur most often
in the bulbomembranous urethra (60%), while its location in
the penile (30%) or prostatic urethra (10%) is less common.
The vast majority (78%) are squamous cell carcinomas and
only 15% transitional cell carcinomas. The remainder (6%)
represent the very rare variant of urethral adenocarcinoma [4].
In females, 55% represent squamous cell carcinoma, 17%
transitional cell carcinoma and 16% adenocarcinoma [5].
The etiology and pathogenesis of urethral carcinoma are
essentially unknown although probable associated factors 
have been identified. The single most important factor for the
prognosis of urethral cancer seems to be its location and extent
at diagnosis and hence its amenability to surgical control.
While symptoms and signs of early urethral cancer are non-
specific in both sexes, tumors of the posterior urethra tend to
be diagnosed at a later stage and, for this reason and because
their radical excision is more invasive and complicated, carry
an unfavorable prognosis.
Because urethral carcinoma is very rare, no single institution
has enough patients to prospectively analyze different treat-
ment options. For this reason, experience with different surgi-
cal treatment options is empirical and often anecdotal.
We report our experience with 6 cases of primary urethral
carcinoma in our institution.
Patients and Case Histories
Six cases of primary urethral cancer, 5 in males and 1 in a female, were
diagnosed and treated at our institution between 1995 and 1999. All cases
suffered from primary urethral carcinoma and, after histological confirma-
tion of urethral carcinoma and extensive clinical staging, were without any
history or evidence of other malignancies of the urinary tract.
Case 1
A 63-year-old man had been suffering from persistent and pronounced
alguria for 6 months. A suspicious papillomatous lesion was seen on ure-
throscopy in the distal penile urethra which was biopsied. Histology con-
firmed a transitional cell carcinoma. After full diagnostic evaluation with-
out any evidence of other sites of transitional cell carcinoma in the urinary
tract, an organ-preserving distal urethrectomy with negative surgical mar-
gins was performed. Tumor stage was pT2 G3. No adjuvant treatment was
given and the patient is free of recurrence 27 months after surgery.
Case 2
A 58-year-old male presented with acute epididymitis when a small
papillomatous lesion resembling condylomata acuminata was seen pro-
truding from the fossa navicularis of the urethra. The lesion was biopsied
and destroyed by laser application. Histology revealed transitional cell car-
cinoma (pTa G2), and human papilloma virus type 16 (HPV-16) was found
in a postoperative urethral swab by polymerase chain reaction. An exten-
sive diagnostic work-up including urinary cytology, transurethral bladder
biopsies and all relevant radiological examinations revealed no evidence of
other malignant lesions. For definitive surgical treatment an organ-pre-
serving distal urethrectomy was performed. The patient has been recur-
rence-free for 5 years and 11 months.
Case 3
A 57-year-old man had noticed a slowly progressive nontender left-sided
inguinal swelling for 1 year. He presented 2 weeks after the onset of re-
current macrohematuria. Urethrocystoscopy showed exophytic papilloma-
tous lesions of the distal penile urethra, and biopsy confirmed transitional
cell carcinoma. Again, no evidence of transitional cell carcinoma at other
sites of the urinary tract was found, and distal urethrectomy of a pT1 G2
lesion was performed with negative surgical margins. Bilateral inguinal
lymphadenectomy revealed unilateral metastatic disease (pN2). Two
courses of an adjuvant polychemotherapy with the MVEC regimen
(methotrexate, vinblastine, etoposide and cisplatinum) were given. The
patient is without evidence of disease 12 months after the cessation of
chemotherapy.
Case 4
A 74-year-old man had noticed a palpable induration of the distal penis.
This was initially suspected to represent Peyronie’s disease by his physi-
cian. On local progression and the development of alguria the patient was
referred 10 months after the initial presentation. Urethrocystoscopy
showed fragile papillomatous lesions in the distal urethra, and cytology
and biopsy confirmed transitional cell carcinoma. Due to extensive infil-
tration of both cavernous bodies a complete penile amputation was per-
formed with complete removal of the local lesion (pT3 G3). No inguinal
lymphadenopathy was clinically seen, but on MRI enlarged lymph nodes
were noticed. Bilateral inguinal lymphadenectomy revealed unilateral
metastatic lymph node disease (pN2). Further staging evaluation gave 
no evidence of other metastatic lesions. Adjuvant chemotherapy with 
2 courses of MVEC was given, which was poorly tolerated by the patient.
Pancytopenia developed during the 2nd cycle which was prematurely ter-
minated. After full recovery, 2 courses of a regimen consisting of paclitaxel
monotherapy were given and well tolerated. The patient has been without
evidence of disease since the cessation of chemotherapy for 12 months.
Case 5
A 51-year-old woman with a history of breast cancer treated successfully
surgically with adjuvant radiotherapy 18 years previously presented with a
nontender swelling at the external urethral meatus which she had noticed
herself. On examination a whitish induration and enlargement of the
meatus of about 1 cm in diameter was seen, which on urethroscopy
covered the distal urethra for about 4 mm while the upper urethra and 
the urinary bladder appeared normal. A biopsy revealed squamous cell
carcinoma. Distal urethrectomy was performed (pT2 G2), however, with a
positive surgical margin.At the time, the patient refused further treatment.
5 months later inguinal lymphadenopathy was noted, and bilateral inguinal
lymphadenectomy was performed which revealed unilateral metastatic
disease. 5 courses of polychemotherapy with methotrexate, bleomycin,
and cisplatinum according to the regimen described by Dexeus et al. [6]
were given and well tolerated. The patient has been free of recurrence for
3 years and 11 months.
Case 6
A 54-year-old man suffering from recurrent bulbous urethral strictures was
referred for urethroplasty. Previously, the patient had undergone internal
urethrotomies for recurrent strictures 3 times in 2 years. After evaluation
for the extent of the stricture, onlay urethroplasty with a buccal mucosal
graft was performed.The postoperative course was uncomplicated, and the
patient discharged free of urinary symptoms with a full urinary stream.
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The patient presented again 6 months later with alguria, poor stream, and
a tender bulbous urethra. After suprapubic catheter drainage, further
evaluation showed a narrowing of the bulbous urethra by partially necrotic
whitish tissue. Biopsy revealed squamous cell carcinoma. Surgical resec-
tion of the bulbous urethra and the prostate via the perineal route were
done with histopathological evidence of incomplete resection.Three courses
of adjuvant chemotherapy with bleomycin, methotrexate and cisplatinum
were given and well tolerated. The patient is at present in remission 
4 months after second-line chemotherapy with paclitaxel and carboplatin.
Results
In the 3 cases of localized carcinoma of the distal urethra in
men (cases 1–3), partial urethrectomy with preservation of 
the penile organ resulted in 100% survival without adjuvant
treatment. All 3 patients are without evidence of disease with
a follow-up ranging from 12 to 71 months.
In the cases with locally advanced tumor and/or lymph node
metastases treatment with surgical excision (complete resec-
tion with penile amputation in 1 case, incomplete resection in
1 male and 1 female case) and adjuvant chemotherapy has
resulted in complete remissions in all 3 cases with a follow-up
ranging between 4 and 47 months so far. In the case after ure-
throplasty (case 6), although the patient is at present without
evidence of disease, progression must be expected while adju-
vant chemotherapy has resulted in significant progression-free
survival in the two other cases.
Discussion
The etiology of urethral carcinoma is essentially unknown in
both genders although associations with probable etiological
factors have been identified. In men these are urethral stric-
ture, a history of venereal disease, and urethritis. A history of
previous or coexisting urethral stricture has been reported in
35% [7], 48% [8] and 88% [9] of cases of primary male urethral
carcinoma. In the series of Ray et al. [8], a history of venereal
disease was noted in 44% of men with primary urethral carci-
noma. In women, urethral caruncle, diverticula, and chronic or
recurrent lower urinary tract infections have been implicated
as predisposing factors for the development of urethral cancer
although the associations are weak [10, 11].
HPV-16 has been found in both primary and metastatic lesions
of 4 of 14 cases of primary male urethral carcinoma [12], thus
providing evidence that this virus is a likely etiologic factor in
primary squamous cell carcinoma of the urethra in males. No
similar association of HPV with urethral cancer has been
reported for women.
Because primary urethral carcinoma is such a rare condition,
reports in the literature consist only of small-scale retro-
spective analyses and case reports. Due to the low number of
patients treated with this condition, there are no prospective
trials analyzing different treatment options. Hence, treatment
decisions will by necessity have to be based on the personal
experience of a few cases and the published experience of
small groups of patients. Transitional cell carcinoma of the
prostatic urethra and the prostate is not discussed here as it
represents a different disease entity which should be treated by
radical cystoprostatectomy and urethrectomy [13].
Generally, for primary urethral carcinoma excision of the lesion
with surgical local control of the disease is and must be the first
treatment option. Primary radiotherapy has been reported in
case reports [14] with following local recurrence, and there is
no valid evidence to support the use of radiotherapy in cases
where curative surgical treatment is possible. With surgical
treatment, the extent of the procedure for the treatment of pri-
mary urethral carcinoma in males is not defined. Also the role
of lymphadenectomy in distal urethral cancer is completely
undefined,and lastly there are no valid guidelines for the chemo-
therapeutic management of metastatic urethral cancer.
The cases reported here illustrate these dilemmas of treatment
decisions that must be made in such cases and also represent
some unusual points of urethral carcinoma. First, although
urethral cancer is more common in women, we have seen more
male patients with this condition. Secondly, the 3 cases with
localized distal urethral carcinoma all had transitional cell car-
cinoma which is unusual (cases 1–3). The finding of HPV-16 in
association with transitional cell carcinoma of the urethra is
also unusual (case 2) and may be coincidental.
The symptoms and signs of urethral cancer are nonspecific, and
in males the diagnosis tends to be delayed for this reason (case
4). A high degree of suspicion is required in cases of recurrent
bulbous urethral strictures (case 6), especially if these are
difficult to treat and have a tendency to bleed profusely with
dilatation or internal urethrotomy [2]. The association of
squamous cell urethral carcinoma and recurrent bulbous
urethral strictures is well supported by retrospective analysis
(see above) although not undisputed. Mandler et al. [15] re-
ported only a 16% previous history of urethral strictures in
males with urethral carcinoma, and in a series of 280 cases of
urethroplasty performed for strictures only 1 patient had a
urethral carcinoma [16]. It is thus not entirely clear whether the
reported associations of the rare primary urethral carcinoma in
males with the very common entities of urethral stricture,
previous history of sexually transmitted disease, and urethritis
are causative in nature.
14–30% of male and female patients with urethral malignancy
will have lymph node spread at diagnosis [8, 17]. Inguinal
lymphadenopathy in urethral cancer (case 3) suggests metasta-
tic disease with a high probability [18]. A high degree of suspi-
cion is required even if no palpable lymph nodes are present,
and staging examinations with a high sensitivity in detecting
nonpalpable inguinal lymph node enlargement such as MRI
may be advisable (case 4).
There is no universally accepted clinical staging system for ure-
thral malignancy. For male urethral cancer the system pro-
posed by Ray and Guinan [8] (with stages 0, A, B, C and D1
and D2) has been used in the USA and was later replaced by
the system proposed by the American Joint Committee on
Cancer which is identical to the TNM system of the UICC used
in Europe [19].
In primary carcinoma of the distal urethra in males the treat-
ment options described in the literature are varied and range
from transurethral resection of the lesion, open resection with
end-to-end anastomosis [20], partial penile amputation and
complete penile amputation to full emasculisation [21].
As in penile carcinoma, the conflicting issues of surgical disease
control versus organ preservation are often difficult to combine
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[22]. While simple transurethral resection of a carcinomatous
urethral lesion seems inadequate and not advisable, preserva-
tion of the penis with partial urethrectomy is appropriate in
cases of superficial (Ta, T1) distal urethral carcinoma in males.
With such a procedure, the glans and corpora cavernosa and
thus the main components, and function of the penile organ are
preserved while a midshaft artificial hypospadia is created,
allowing uninhibited voiding.The 3 cases with distal transitional
cell urethral carcinoma we treated in this manner (cases 1–3)
were satisfied and are recurrence-free.
Thus, while in our opinion it is essential to provide safe and
adequate surgical control of the disease it is of equal impor-
tance to avoid surgical over-treatment with complete penile
amputation which can have debilitating consequences for
some men.
Advanced disease with metastatic lymph node spread must be
surgically explored by inguinal lymphadenectomy which must
be considered to have mainly diagnostic value. Bilateral groin
dissection still carries a high risk of complications and asso-
ciated morbidity in large series of penile cancer patients
[23–25].The role of prophylactic lymphadenectomy in urethral
cancer is not defined. Lymphadenectomy is undisputably indi-
cated in cases of enlarged nodes and suspected metastatic
disease (cases 3–5).
However, removal of metastatic inguinal lymph nodes cannot
be considered to be curative, and histological proof of lymph
node involvement necessitates systemic therapy although
distant metastastic spread seems to be a late occurrence in
urethral cancer. Since there are no trials of chemotherapy for
urethral carcinoma, the regimens employed will have to be
those employed for histologically similiar tumor entities at
other sites. Thus, for transitional cell carcinoma of the urethra,
MVEC or MVAC regimens are used, with the options to use
gemcitabine or paclitaxel as second-line treatments (case 3 and
4). For squamous cell carcinoma of the urethra, we have used
regimens following the recommended treatment for metastatic
squamous cell carcinoma of the penis (cases 5 and 6). The
chemotherapy described by Dexeus et al. [6, 26] is the most
commonly used treatment regimen for this purpose. However,
the rationale for using this regimen is also based on a very
small group of patients.
Incomplete resection of the tumor due to advanced local
disease carries a poor prognosis (cases 5 and 6). With the diffi-
culties of complete resection encountered in female urethral
cancer when radical cystourethrectomy is not done, and in car-
cinoma of the proximal bulbous male urethra, rapid disease
progression is likely.When surgical control of the disease is not
possible, systemic chemotherapy is indicated and should be
undertaken as soon as possible.
Thus in females with urethral cancer, radical surgical treatment
with complete urethrectomy or cystourethrectomy plus
urinary diversion must be considered as local excision even of
distal urethral carcinoma carries a high risk of progression. In
the case described (case 5), however, inguinal metastases
following incomplete resection (R1) of the primary tumor
were successfully treated by lymphadenectomy and adjuvant
chemotherapy.
In the rare case of a carcinoma developing after urethroplasty
radical surgical excision is difficult and oncologically probably
not feasible (case 6). It is possible that in this case squamous
cell carcinoma of the urethra had been present as the under-
lying cause of the recurrent bulbous strictures and went un-
detected at the time of urethroplasty. Thus, a high degree of
suspicion is warranted and perhaps routine histological exami-
nation in cases of recurrent bulbous strictures advisable.
Because of the rarity of urethral carcinoma, attempts to devel-
op standardized treatment based on prospective studies have
been unsuccessful [27]. For this reason definite and evidence-
based recommendations are not available. Thus, the role of
radiotherapy in the treatment of this disorder is largely un-
defined. In low-stage disease of the female urethra interstitial
radiation therapy has resulted in cure rates of 60–80% [28, 29].
In more advanced stages of female urethral carcinoma where
radical therapy is required, reported 5-year survival rates after
radiotherapy vary between 0 and 57% [5, 14, 30, 31] compared
to those after surgery of 10–17% [32]. Preoperative radio-
therapy followed by anterior exenteration has resulted in 
5-year survival of around 50% in small series [31, 33, 34].
In male urethral cancer, most authors agree that surgical exci-
sion remains the preferred mode of treatment. Radiotherapy
has therefore been reserved mainly for patients who have failed
local control or have refused surgical treatment. The reported
radiotherapy results  have thus been disappointing [27]. How-
ever, there may be a role for radiotherapy in male urethral
carcinoma in combination with chemotherapy for downstaging
of locally advanced lesions before surgical resection [35].
The role of lymphadenectomy in patients with suspected
lymph node disease is undisputed. However, adjuvant treat-
ment options in patients with lymph node disease is undefined.
Different institutions undertake different efforts to develop
new modalities of treatment, including combination radio-
therapy, chemotherapy and surgery. We believe that adjuvant
chemotherapy is certainly indicated when lymph node disease
is seen as this is likely to represents systemic rather than re-
gional disease only.
The prognosis of urethral cancer in localized disease with com-
plete surgical resection is good while that of advanced disease
remains poor. The overall survival of all stages is around 50%,
but only 5–15% for posterior tumors [7, 21, 36, 37]. For urethral
carcinoma in females as well as for posterior urethral lesions in
males, the prognosis is less good than for anterior urethral
lesions in males. A 100% disease-free and disease-specific sur-
vival rate has been reported for male patients with carcinoma
originating in the fossa navicularis, comparing to 55% for penile
urethral and 25% for bulbomembranous urethral carcinomas.
These data and our own experience support that complete
surgical control must be the first treatment goal and that
organ-preserving surgery in male anterior urethral carcinoma
is justified. The considerably worse prognosis of male posterior
and female urethral carcinoma necessitates more aggressive
surgery. The poor prognosis of metastatic disease in our view
requires systemic treatment and thus polychemotherapy.
Conclusions
Primary urethral carcinoma as a rare condition represents a
challenge to the urologic surgeon since, due to the lack of
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clinical trials, no valid treatment guidelines based on large-scale experience are
available. Radical surgical treatment is the first treatment option.Organ preservation
in distal urethral carcinoma in males is feasible and justified. Urethral carcinoma in
females and proximal urethral carcinoma in males requires a much more invasive
and radical surgical approach. Staging should include radiological evaluation for
inguinal and pelvic lymph node spread, and bilateral lymphadenectomy should be
undertaken if suspicious findings are seen. Advanced and metastatic disease can be
treated by adjuvant chemotherapy but carries a poor prognosis.
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